Amgen grabs the axe, chops up to 2,600 jobs
(UPDATED: See below.)
The biotech colossus Amgen, stung by safety and regulatory issues that hit hard at sales of its core anemia drugs, announced today that it will cut its headcount between 12 percent and 14 percent, ratchet back on new plant construction, close production operations and prioritize its research spending. The giant biotech said these measures will yield savings of up to $1.3 billion by next year.
The restructuring is the first in Amgen’s history, and virtually… Continue Reading
Biotech Roundup: Heart-disease biomarkers, drugs that go too far, “non-profit” drugs
(Note: This item has been copied over to the Life Sciences page from its original location on the VentureBeat main page. To view it in its original context, with comments, click here.)
Cautionary tales: An occasional look at events with potential long-term impact for biotechnology
Personalized medicine takes a hit — Scientists have spent more than a decade scouring the human genome to identify genetic alterations that might predict your risk of developing, say, heart trouble or cancer…. Continue Reading
Biotech Roundup: Heart-disease biomarkers, drugs that go too far, “non-profit” drugs
Cautionary tales: An occasional look at events with potential long-term impact for biotechnology
Personalized medicine takes a hit — Scientists have spent more than a decade scouring the human genome to identify genetic alterations that might predict your risk of developing, say, heart trouble or cancer. Now, however, a new study (subscription required) Wednesday in the Journal of the American Medical Association suggests that many of these disease “biomarkers” identified so far may be little more than junk…. Continue Reading